Rev was shown to synergize with checkpoint PD-1/PD-1L blockage to enhance anti–MM immune responses [70], and Rev can lead to increased IFN-γ production in antigen-specific T cells, even in the presence of CD8+CD28- Tregs [67], as well as in MM-derived CD8+ T cells stimulated with anti-CD3 and anti-CD28 antibodies [71]. The gene discussed is IFNG; the disease is Miyoshi myopathy.